CAD 204520
Alternative Names: CAD-204520; Cad204520Latest Information Update: 28 Jul 2023
At a glance
- Originator CaDo Biotechnology
- Class Antineoplastics; Small molecules
- Mechanism of Action Apoptosis stimulants; Sarcoplasmic reticulum calcium-transporting ATPase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Precursor T-cell lymphoblastic leukaemia-lymphoma
Most Recent Events
- 28 Jul 2023 No recent reports of development identified for preclinical development in Precursor-T-cell-lymphoblastic-leukaemia-lymphoma in Denmark (PO)
- 26 Oct 2019 Pharmacodynamics data from a preclinical trial in Precursor T-cell lymphoblastic leukaemia lymphoma presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR-2019)
- 13 Jun 2019 Preclinical trials in Precursor T-cell lymphoblastic leukaemia-lymphoma in Denmark (PO)